Cargando…

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia

BACKGROUND: A Wilms’ tumor 1 (WT1) oral vaccine, Bifidobacterium longum (B. longum) 420, in which the bacterium is used as a vector for WT1 protein, triggers immune responses through cellular immunity consisting of cytotoxic T lymphocytes (CTLs) and other immunocompetent cells (e.g., helper T cells)...

Descripción completa

Detalles Bibliográficos
Autores principales: Minagawa, Hikaru, Hashii, Yoshiko, Nakajima, Hiroko, Fujiki, Fumihiro, Morimoto, Soyoko, Nakata, Jun, Shirakawa, Toshiro, Katayama, Takane, Tsuboi, Akihiro, Ozono, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940413/
https://www.ncbi.nlm.nih.gov/pubmed/36803483
http://dx.doi.org/10.1186/s12885-023-10547-5
_version_ 1784891073033666560
author Minagawa, Hikaru
Hashii, Yoshiko
Nakajima, Hiroko
Fujiki, Fumihiro
Morimoto, Soyoko
Nakata, Jun
Shirakawa, Toshiro
Katayama, Takane
Tsuboi, Akihiro
Ozono, Keiichi
author_facet Minagawa, Hikaru
Hashii, Yoshiko
Nakajima, Hiroko
Fujiki, Fumihiro
Morimoto, Soyoko
Nakata, Jun
Shirakawa, Toshiro
Katayama, Takane
Tsuboi, Akihiro
Ozono, Keiichi
author_sort Minagawa, Hikaru
collection PubMed
description BACKGROUND: A Wilms’ tumor 1 (WT1) oral vaccine, Bifidobacterium longum (B. longum) 420, in which the bacterium is used as a vector for WT1 protein, triggers immune responses through cellular immunity consisting of cytotoxic T lymphocytes (CTLs) and other immunocompetent cells (e.g., helper T cells). We developed a novel, oral, helper epitope-containing WT1 protein vaccine (B. longum 2656) to examine whether or not B. longum 420/2656 combination further accelerates the CD4(+) T cell help-enhanced antitumor activity in a model of murine leukemia. METHODS: C1498-murine WT1—a genetically-engineered, murine leukemia cell line to express murine WT1—was used as tumor cell. Female C57BL/6 J mice were allocated to the B. longum 420, 2656, and 420/2656 combination groups. The day of subcutaneous inoculation of tumor cells was considered as day 0, and successful engraftment was verified on day 7. The oral administration of the vaccine by gavage was initiated on day 8. Tumor volume, the frequency and phenotypes of WT1-specific CTLs in CD8(+) T cells in peripheral blood (PB) and tumor-infiltrating lymphocytes (TILs), as well as the proportion of interferon-gamma (INF-γ)-producing CD3(+)CD4(+) T cells pulsed with WT1(35–52) peptide in splenocytes and TILs were determined. RESULTS: Tumor volume was significantly smaller (p < 0.01) in the B. longum 420/2656 combination group than in the B. longum 420 group on day 24. WT1-specific CTL frequency in CD8(+) T cells in PB was significantly greater in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 (p < 0.05) and 6 (p < 0.01). The proportion of WT1-specific, effector memory CTLs in PB increased significantly in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 and 6 (p < 0.05 each). WT1-specific CTL frequency in intratumoral CD8(+) T cells and the proportion of IFN-γ-producing CD3(+)CD4(+) T cells in intratumoral CD4(+) T cells increased significantly (p < 0.05 each) in the B. longum 420/2656 combination group than in the 420 group. CONCLUSIONS: B. longum 420/2656 combination further accelerated antitumor activity that relies on WT1-specific CTLs in the tumor compared with B. longum 420.
format Online
Article
Text
id pubmed-9940413
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99404132023-02-21 Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia Minagawa, Hikaru Hashii, Yoshiko Nakajima, Hiroko Fujiki, Fumihiro Morimoto, Soyoko Nakata, Jun Shirakawa, Toshiro Katayama, Takane Tsuboi, Akihiro Ozono, Keiichi BMC Cancer Research BACKGROUND: A Wilms’ tumor 1 (WT1) oral vaccine, Bifidobacterium longum (B. longum) 420, in which the bacterium is used as a vector for WT1 protein, triggers immune responses through cellular immunity consisting of cytotoxic T lymphocytes (CTLs) and other immunocompetent cells (e.g., helper T cells). We developed a novel, oral, helper epitope-containing WT1 protein vaccine (B. longum 2656) to examine whether or not B. longum 420/2656 combination further accelerates the CD4(+) T cell help-enhanced antitumor activity in a model of murine leukemia. METHODS: C1498-murine WT1—a genetically-engineered, murine leukemia cell line to express murine WT1—was used as tumor cell. Female C57BL/6 J mice were allocated to the B. longum 420, 2656, and 420/2656 combination groups. The day of subcutaneous inoculation of tumor cells was considered as day 0, and successful engraftment was verified on day 7. The oral administration of the vaccine by gavage was initiated on day 8. Tumor volume, the frequency and phenotypes of WT1-specific CTLs in CD8(+) T cells in peripheral blood (PB) and tumor-infiltrating lymphocytes (TILs), as well as the proportion of interferon-gamma (INF-γ)-producing CD3(+)CD4(+) T cells pulsed with WT1(35–52) peptide in splenocytes and TILs were determined. RESULTS: Tumor volume was significantly smaller (p < 0.01) in the B. longum 420/2656 combination group than in the B. longum 420 group on day 24. WT1-specific CTL frequency in CD8(+) T cells in PB was significantly greater in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 (p < 0.05) and 6 (p < 0.01). The proportion of WT1-specific, effector memory CTLs in PB increased significantly in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 and 6 (p < 0.05 each). WT1-specific CTL frequency in intratumoral CD8(+) T cells and the proportion of IFN-γ-producing CD3(+)CD4(+) T cells in intratumoral CD4(+) T cells increased significantly (p < 0.05 each) in the B. longum 420/2656 combination group than in the 420 group. CONCLUSIONS: B. longum 420/2656 combination further accelerated antitumor activity that relies on WT1-specific CTLs in the tumor compared with B. longum 420. BioMed Central 2023-02-20 /pmc/articles/PMC9940413/ /pubmed/36803483 http://dx.doi.org/10.1186/s12885-023-10547-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Minagawa, Hikaru
Hashii, Yoshiko
Nakajima, Hiroko
Fujiki, Fumihiro
Morimoto, Soyoko
Nakata, Jun
Shirakawa, Toshiro
Katayama, Takane
Tsuboi, Akihiro
Ozono, Keiichi
Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
title Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
title_full Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
title_fullStr Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
title_full_unstemmed Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
title_short Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
title_sort enhanced antitumor activity of a novel, oral, helper epitope-containing wt1 protein vaccine in a model of murine leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940413/
https://www.ncbi.nlm.nih.gov/pubmed/36803483
http://dx.doi.org/10.1186/s12885-023-10547-5
work_keys_str_mv AT minagawahikaru enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT hashiiyoshiko enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT nakajimahiroko enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT fujikifumihiro enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT morimotosoyoko enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT nakatajun enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT shirakawatoshiro enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT katayamatakane enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT tsuboiakihiro enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia
AT ozonokeiichi enhancedantitumoractivityofanoveloralhelperepitopecontainingwt1proteinvaccineinamodelofmurineleukemia